134 related articles for article (PubMed ID: 33333529)
21. [Intravesical therapy with mitomycin through electromotive drug administration].
Verri C; Liberati E; Celestino F; De Carlo F; Torelli F; Di Stasi SM
Urologia; 2013; 80(2):105-11. PubMed ID: 23852927
[TBL] [Abstract][Full Text] [Related]
22. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
23. [Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.].
Coenen JJMJH; van Valenberg FJP; Arends TJH; Witjes JA
Arch Esp Urol; 2018 May; 71(4):400-408. PubMed ID: 29745929
[TBL] [Abstract][Full Text] [Related]
24. Intravesical Treatment with Electro-Mediated Administration of Mytomicin C as Prophylaxis for Intermediate and High-Risk Nonmuscle-Invasive Bladder Cancer: A Retrospective Multicenter Study.
Carando R; Zazzara M; Cotrufo S; Ludovico GM
Urol Int; 2019; 103(3):285-290. PubMed ID: 31461726
[TBL] [Abstract][Full Text] [Related]
25. Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
Di Stasi SM; Liberati E; Dutto L; Verri C
Arch Ital Urol Androl; 2008 Dec; 80(4):157-61. PubMed ID: 19235432
[TBL] [Abstract][Full Text] [Related]
26. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
Kalsi J; Harland SJ; Feneley MR
Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
[TBL] [Abstract][Full Text] [Related]
27. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC).
Colombo R; Salonia A; Leib Z; Pavone-Macaluso M; Engelstein D
BJU Int; 2011 Mar; 107(6):912-8. PubMed ID: 21029314
[TBL] [Abstract][Full Text] [Related]
30. Selecting initial therapy for bladder cancer.
Soloway MS
Cancer; 1987 Aug; 60(3 Suppl):502-13. PubMed ID: 3109725
[TBL] [Abstract][Full Text] [Related]
31. A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer.
Chen CH; Yang HJ; Shun CT; Huang CY; Huang KH; Yu HJ; Pu YS
Urol Oncol; 2012; 30(4):421-7. PubMed ID: 20870427
[TBL] [Abstract][Full Text] [Related]
32. The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer.
Onishi T; Sekito S; Shibahara T; Uchida K; Sasaki T
Scand J Urol; 2018; 52(5-6):385-388. PubMed ID: 30628540
[TBL] [Abstract][Full Text] [Related]
33. Intravesical electro-osmotic administration of mitomycin C.
Di Stasi SM; Verri C; Celestino F; De Carlo F; Pagliarulo V
Urologia; 2016 Oct; 83(Suppl 2):18-23. PubMed ID: 27716887
[TBL] [Abstract][Full Text] [Related]
34. [Assessment of the optimization of the conditions of mitomycin C intravesical instillation completion in the setting of non-muscle invasive bladder cancer treatment].
Lailler G; Neuzillet Y; Rouanne M; Lebret T
Prog Urol; 2016 Feb; 26(2):79-82. PubMed ID: 26653577
[TBL] [Abstract][Full Text] [Related]
35. Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection.
Shapiro O; Jones K; Wang C; Landas S; Haas GP
Can J Urol; 2006 Dec; 13(6):3317-20. PubMed ID: 17187694
[TBL] [Abstract][Full Text] [Related]
36. Intravesical adjuvant therapy using mitomycin C.
Islam MA; Bhuiyan ZH; Shameem IA
Mymensingh Med J; 2006 Jan; 15(1):40-4. PubMed ID: 16467761
[TBL] [Abstract][Full Text] [Related]
37. The role of hyperthermia as a treatment for non-muscle invasive bladder cancer.
Bahouth Z; Halachmi S; Moskovitz B; Nativ O
Expert Rev Anticancer Ther; 2016; 16(2):189-98. PubMed ID: 26618756
[TBL] [Abstract][Full Text] [Related]
38. Ablative Intravesical Chemotherapy for Small Recurrent Non-Muscle-Invasive Bladder Cancer: A Prospective Study.
Decaestecker K; Lumen N; Ringoir A; Oosterlinck W
Urol Int; 2016; 96(1):14-9. PubMed ID: 25791565
[TBL] [Abstract][Full Text] [Related]
39. Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection.
Ba M; Cui S; Wang B; Long H; Yan Z; Wang S; Wu Y; Gong Y
Oncol Rep; 2017 May; 37(5):2761-2770. PubMed ID: 28405683
[TBL] [Abstract][Full Text] [Related]
40. [Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer].
Rouprêt M; Neuzillet Y; Larré S; Pignot G; Coloby P; Rébillard X; Mongiat-Artus P; Chartier-Kastler E; Soulié M; Pfister C;
Prog Urol; 2012 Nov; 22(15):920-31. PubMed ID: 23102014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
